Conclusion
In conclusion, recognition and diagnosis of TA-TMA is challenging. Clinical utility of complement blockage with eculizumab is limited in terms of therapeutic efficacy, response monitoring and financial implications. Further prospective research studies on alternative agents are warranted to improve treatment and outcomes of TA-TMA.